Covid-19 treatment hopes as GlaxoSmithKline’s antibody drug moves onto phase 3 trial
A potential new coronavirus antibody treatment made by a British pharmaceutical giant has moved into late stage trials. Brentford-based GlaxoSmithKline (GSK) said its treatment – known as Vir-7831 – could be rolled out by 2021 if its proven to be effective and safe. The drug uses antibodies – proteins found in people who have survived Covid-19 … Read more